Evidence map›Paper›PMID 37378994›Full record

Observational studyJAMA dermatology2023

Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.

Alain Lescoat, Suiyuan Huang, Patricia E Carreira, Elise Siegert, Jeska de Vries-Bouwstra, Jörg H W Distler, Vanessa Smith, Francesco Del Galdo, Branimir Anic, Nemanja Damjanov and 9 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in JAMA dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Management of adrenocortical adenoma in systemic sclerosis: A case report.The Journal of international medical research · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 16 institutions in 14 countries.

Alain LescoatUniversity of Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Rennes, France.
Suiyuan HuangDivision of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor.
Patricia E CarreiraRheumatology Department, University Hospital 12th of October, Madrid, Spain.
Elise SiegertCharité University Hospital, Berlin, Germany.
Jeska de Vries-BouwstraDepartment of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
Jörg H W DistlerUniversity of Erlangen-Nuremberg, Erlangen, Germany.
Vanessa SmithDepartment of Rheumatology, Ghent University Hospital, Ghent, Belgium.
Francesco Del GaldoInstitute of Rheumatic and Musculoskeletal Medicine and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom.
Branimir AnicDivision of Clinical Immunology and Rheumatology, University of Zagreb School of Medicine and University Hospital Centre, Zagreb, Croatia.
Nemanja DamjanovInstitute of Rheumatology, Faculty of Medicine University of Belgrade, Belgrade, Serbia.
Simona RednicDepartment of Rheumatology, Emergency County Teaching Hospital, Cluj-Napoca, Romania.
Camillo RibiDepartment of Clinical Immunology and Allergy, Lausanne, Switzerland.
Dominique Farge BancelDepartment of Internal Medicine: CRMR MATHEC, Maladies Auto-Immunes et Thérapie Cellulaire, Centre de Référence des Maladies Auto-Immunes Systémiques Rares d'Ile-de-France, FAI2R, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.
Anna-Maria Hoffmann-VoldDepartment of Rheumatology, Rikshospitalet University Hospital, Oslo, Norway.
Armando GabrielliArche Polytechnic University, Institute of Clinical Medicine, University of Ancona, Ancona, Italy.
Oliver DistlerDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Dinesh KhannaDivision of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor.
Yannick AllanoreService de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France.
EUSTAR collaborators
University of Michigan · USCentre National de la Recherche Scientifique · FRCharité - Universitätsmedizin Berlin · DEClinical Emergency Hospital Bucharest · ROFriedrich-Alexander-Universität Erlangen-Nürnberg · DEGhent University Hospital · BELeiden University Medical Center · NLMarche Polytechnic University · ITOslo University Hospital · NOResearch Institute Hospital 12 de Octubre · ESUniversité Paris Cité · FRUniversity Hospital Centre Zagreb · HRUniversity of Belgrade · RSUniversity of Leeds · GBUniversity of Zurich · CHInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Systemic sclerosis (SSc) sine scleroderma (ssSSc) is a subset of SSc defined by the absence of skin fibrosis. Little is known about the natural history and skin manifestations among patients with ssSSc. Objective: To characterize the clinical phenotype of patients with ssSSc compared with patients with limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) within the EUSTAR database. Design, Setting, and Participants: This longitudinal observational cohort study based on the international EUSTAR database included all patients fulfilling the classification criteria for SSc assessed by the modified Rodnan Skin score (mRSS) at inclusion and with at least 1 follow-up visit; ssSSc was defined by the absence of skin fibrosis (mRSS = 0 and no sclerodactyly) at all available visits. Data extraction was performed in November 2020, and data analysis was performed from April 2021 to April 2023. Main Outcomes and Measures: Main outcomes were survival and skin manifestations (onset of skin fibrosis, digital ulcers, telangiectasias, puffy fingers). Results: Among the 4263 patients fulfilling the inclusion criteria, 376 (8.8%) were classified as having ssSSc (mean [SD] age, 55.3 [13.9] years; 345 [91.8%] were female). At last available visit, in comparison with 708 patients with lcSSc and 708 patients with dcSSc with the same disease duration, patients with ssSSc had a lower prevalence of previous or current digital ulcers (28.2% vs 53.1% in lcSSc; P < .001; and 68.3% in dcSSc; P < .001) and puffy fingers (63.8% vs 82.4% in lcSSc; P < .001; and 87.6% in dcSSc; P < .001). By contrast, the prevalence of interstitial lung disease was similar in ssSSc and lcSSc (49.8% and 57.1%; P = .03) but significantly higher in dcSSc (75.0%; P < .001). Skin telangiectasias were associated with diastolic dysfunction in patients with ssSSc (odds ratio, 4.778; 95% CI, 2.060-11.081; P < .001). The only independent factor for the onset of skin fibrosis in ssSSc was the positivity for anti-Scl-70 antibodies (odds ratio, 3.078; 95% CI, 1.227-7.725; P = .02). Survival rate was higher in patients with ssSSc (92.4%) compared with lcSSc (69.4%; P = .06) and dcSSc (55.5%; P < .001) after up to 15 years of follow-up. Conclusions and Relevance: Systemic sclerosis sine scleroderma should not be neglected considering the high prevalence of interstitial lung disease (>40%) and SSc renal crisis (almost 3%). Patients with ssSSc had a higher survival than other subsets. Dermatologists should be aware that cutaneous findings in this subgroup may be associated with internal organ dysfunction. In particular, skin telangiectasias in ssSSc were associated with diastolic heart dysfunction.

Indexed as

Lung Diseases, InterstitialScleroderma, DiffuseScleroderma, SystemicTelangiectasisFemaleFibrosisHumansMalePrognosisSkin Ulcer

Identifiers

PMID37378994
PMCPMC10308295
OpenAlexW4382344802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.